프로티아
Financials
Valuation Metrics
프로티아's Market Cap is ₩462B. At end of 2025 it was ₩536B. Ranked #1744 of 2,410 in KR market (top 72%), #1058 of 1,631 on KOSDAQ (top 65%), #72 of 94 in Health Care Equipment & Services (top 77%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 46.17B KRW | KR#1,744/2,410 Sec#72/94 |
| Revenue | 17.75B KRW | KR#2,169/2,410 Sec#73/94 |
| Net Income | 5.50B KRW | KR#1,171/2,410 Sec#37/94 |
| Total Assets | 33.03B KRW | KR#2,311/2,410 Sec#84/94 |
| Net Assets | 30.70B KRW | KR#2,163/2,410 Sec#77/94 |
| Employees | 89 | KR#1,728/2,410 Sec#68/94 |
| Value | ||
| P/E | 8.40x | KR#778/2,410 Sec#23/94 |
| P/B | 1.50x | KR#1,841/2,410 Sec#61/94 |
| PEG | 0.09x | KR#422/2,410 Sec#19/94 |
| P/S | 2.60x | KR#1,978/2,410 Sec#64/94 |
| EV/EBITDA | 9.27x | KR#634/2,410 Sec#22/94 |
| FCF Yield | 6.51% | KR#810/2,410 Sec#20/94 |
| Profitability | ||
| ROE | 17.91% | KR#213/2,410 Sec#8/94 |
| ROA | 16.65% | KR#84/2,410 Sec#5/94 |
| Op. Margin | 26.27% | KR#84/2,410 Sec#5/94 |
| Revenue Growth | 42.75% | KR#258/2,410 Sec#13/94 |
| Earnings Growth | 92.23% | KR#414/2,410 Sec#20/94 |
| Financial Health | ||
| Debt Ratio | 7.60% | KR#81/2,410 Sec#5/94 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/94 |
| FCF | 3.00B KRW | KR#1,018/2,410 Sec#29/94 |
| Cash | 2.96B KRW | KR#2,163/2,410 Sec#86/94 |
| Current Ratio | 14.79x | KR#50/2,410 Sec#6/94 |
| Net Debt/EBITDA | -0.64x | KR#457/2,410 Sec#16/94 |
| Performance | ||
| 1Y Return | 18.83% | KR#298/2,410 Sec#7/94 |
| 1M Return | -11.59% | KR#864/2,410 Sec#32/94 |
| From 52W High | -21.98% | KR#179/2,410 Sec#4/94 |
| 1Y MDD | -42.06% | KR#639/2,410 Sec#21/94 |
| Trading | ||
| Volume | 14,425 shares | KR#1,410/2,410 Sec#61/94 |
| Trading Value | 52.1M KRW | KR#1,520/2,410 Sec#65/94 |
| Foreign Own. | 2.03% | KR#1,612/2,410 Sec#59/94 |
| Per Share | ||
| EPS | 427 KRW | KR#1,052/2,410 Sec#31/94 |
| BPS | 2,383 KRW | KR#1,993/2,410 Sec#64/94 |
Company Info
Protia, established in 2000 and transferred its listing to the KOSDAQ Market in 2023, develops, manufactures, and sells medical devices based on core immunodiagnostic technology. The company produces and supplies human-use products with the world's highest number of simultaneous allergy diagnostic technologies, the first domestic pet products, and the first antibiotic susceptibility testing products utilizing a capacitance measurement method. Protia possesses development capabilities for 192-line allergy diagnostic products and pursues technological innovation by expanding into domestic and international markets. Protia is headquartered in Gangseo-gu, Seoul.